Showing results (351-360 of 776) with videos related to

Sort By:
Pageof 78
Blood|May 1, 1990
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasmaP J Declerck, H R Lijnen, M Verstreken, et al.
European Journal of Biochemistry|October 1, 1979
Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasminS A Cederholm-Williams, F De Cock, H R Lijnen, et al.
Biochemistry|June 4, 1998
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3)F Ugwu, B Van Hoef, A Bini, et al.
European Journal of Biochemistry|October 13, 2000
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activatorB Arza, M F Hoylaerts, J Félez, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 28, 1998
Oxidized low density lipoproteins in patients with transplant-associated coronary artery diseaseP Holvoet, J M Stassen, J Van Cleemput, et al.
Thrombosis and Haemostasis|February 28, 1984
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activationH R Lijnen, J Soria, C Soria, et al.
European Journal of Biochemistry|November 15, 1988
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160H R Lijnen, L Nelles, B Van Hoef, et al.
Biochemistry|January 13, 2000
Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium SpH R Lijnen, B Van Hoef, F Ugwu, et al.
Human Gene Therapy|January 26, 2000
Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancerB De Geest, S Van Linthout, M Lox, et al.
Thrombosis and Haemostasis|April 26, 2000
Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in miceH Matsuno, O Kozawa, S Ueshima, et al.
Pageof 78